EWTX
Edgewise Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$43.07
+2.67%Aug 6, 2026, 00:00 UTC
Edgewise Therapeutics reported a net loss of $57.3 million for Q2 2026, with R&D expenses of $47.5 million and G&A expenses of $14.4 million.
Jul 13, 2026, 12:30 UTC
Edgewise Therapeutics completed the sale of sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion.
Jun 16, 2026, 17:40 UTC
Edgewise Therapeutics released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial for a heart drug.
Source:Jun 5, 2026, 03:37 UTC
Edgewise Therapeutics sold its muscular dystrophy program to Servier for $2.65 billion, receiving $1.55 billion upfront.
Source:Jun 2, 2026, 16:15 UTC
Edgewise Therapeutics agreed to divest its neuromuscular business to Servier for $2.65 billion.
Source:Jun 1, 2026, 00:00 UTC
Edgewise Therapeutics agreed to sell its neuromuscular program including the sevasemten compound to Servier Pharmaceuticals LLC and Les Laboratoires Servier for $1.55 billion upfront plus potential milestones.